文献速递骨软组织肉瘤与黑色素瘤

一线纳武利尤单抗联合瑞拉利单抗对比纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤:基于RELATIVITY-047与CheckMate 067试验数据的间接治疗比较

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
PubMed 文献 · J Clin Oncol · 2024-08-13

该间接治疗比较利用RELATIVITY-047和CheckMate 067试验的患者个体数据,经逆概率治疗加权校正基线特征后,比较纳武利尤单抗联合瑞拉利单抗(n=339)与纳武利尤单抗联合伊匹木单抗(n=297)一线治疗晚期黑色素瘤的疗效与安全性。结果显示两组无进展生存期、确认客观缓解率、总生存期和黑色素瘤特异性生存期均相似,但纳武利尤单抗联合瑞拉利单抗的3-4级治疗相关不良事件和导致停药的治疗相关不良事件更少。

要点

  • 经逆概率治疗加权后,纳武利尤单抗联合瑞拉利单抗与纳武利尤单抗联合伊匹木单抗的无进展生存期相似(HR 1.08,95%CI 0.88-1.33)。
  • 纳武利尤单抗联合瑞拉利单抗的3-4级治疗相关不良事件发生率为23%,纳武利尤单抗联合伊匹木单抗为61%。
  • 导致停药的任何级别治疗相关不良事件发生率,纳武利尤单抗联合瑞拉利单抗为17%,纳武利尤单抗联合伊匹木单抗为41%。

核心结论

  • 在未经治疗的晚期黑色素瘤患者中,纳武利尤单抗联合瑞拉利单抗在总体人群(包括大多数但非全部亚组)中显示出与纳武利尤单抗联合伊匹木单抗相似的疗效,且安全性更优;结果应谨慎解读。

研究设计与样本

  • 基于II/III期RELATIVITY-047试验和III期CheckMate 067试验患者个体数据的间接治疗比较,采用逆概率治疗加权校正基线特征差异。
  • 最短随访时间:RELATIVITY-047为33个月,CheckMate 067为36个月,以最佳对齐评估。
  • 分析人群:纳武利尤单抗联合瑞拉利单抗组n=339,纳武利尤单抗联合伊匹木单抗组n=297。
  • 采用Cox回归模型比较无进展生存期、总生存期和黑色素瘤特异性生存期,采用逻辑回归模型比较确认客观缓解率;亚组分析为探索性。

主要发现

  • 纳武利尤单抗联合瑞拉利单抗组对比纳武利尤单抗联合伊匹木单抗组的无进展生存期:HR 1.08(95%CI 0.88-1.33)。
  • 纳武利尤单抗联合瑞拉利单抗组对比纳武利尤单抗联合伊匹木单抗组的确认客观缓解率:OR 0.91(95%CI 0.73-1.14)。
  • 纳武利尤单抗联合瑞拉利单抗组对比纳武利尤单抗联合伊匹木单抗组的总生存期:HR 0.94(95%CI 0.75-1.19)。
  • 纳武利尤单抗联合瑞拉利单抗组对比纳武利尤单抗联合伊匹木单抗组的黑色素瘤特异性生存期:HR 0.86(95%CI 0.67-1.12)。
  • 亚组比较显示,在肢端黑色素瘤、BRAF突变黑色素瘤和乳酸脱氢酶>2倍正常上限的亚组中,数值上更倾向于纳武利尤单抗联合伊匹木单抗,但受小样本量限制。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 亚组比较为探索性,且受小样本量限制。
  • 结果应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nivolumab plus relatlimab and nivolumab plus ipilimumab have been approved for advanced melanoma on the basis of the phase II/III RELATIVITY-047 and phase III CheckMate 067 trials, respectively. As no head-to-head trial comparing these regimens exists, an indirect treatment comparison was conducted using patient-level data from each trial. METHODS: Inverse probability of treatment weighting (IPTW) adjusted for baseline characteristic differences. Minimum follow-ups (RELATIVITY-047, 33 months; CheckMate 067, 36 months) were selected to best align assessments. Outcomes included progression-free survival (PFS), confirmed objective response rate (cORR), and melanoma-specific survival (MSS) per investigator; overall survival (OS); and treatment-related adverse events (TRAEs). A Cox regression model compared PFS, OS, and MSS. A logistic regression model compared cORRs. Subgroup analyses were exploratory. RESULTS: After IPTW, key baseline characteristics were balanced for nivolumab plus relatlimab (n = 339) and nivolumab plus ipilimumab (n = 297). Nivolumab plus relatlimab demonstrated similar PFS (hazard ratio [HR], 1.08 [95% CI, 0.88 to 1.33]), cORR (odds ratio, 0.91 [95% CI, 0.73 to 1.14]), OS (HR, 0.94 [95% CI, 0.75 to 1.19]), and MSS (HR, 0.86 [95% CI, 0.67 to 1.12]) to nivolumab plus ipilimumab. Subgroup comparisons showed larger numerical differences favoring nivolumab plus ipilimumab with acral melanoma, BRAF-mutant melanoma, and lactate dehydrogenase >2 × upper limit of normal, but were limited by small samples. Nivolumab plus relatlimab was associated with fewer grade 3-4 TRAEs (23% v 61%) and any-grade TRAEs leading to discontinuation (17% v 41%). CONCLUSION: Nivolumab plus relatlimab demonstrated similar efficacy to nivolumab plus ipilimumab in the overall population, including most-but not all-subgroups, and improved safety in patients with untreated advanced melanoma. Results should be interpreted with caution.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Long GV, Lipson EJ, Hodi FS, et al. First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. J Clin Oncol. 2024. PMID: 39137386. doi:10.1200/JCO.24.01125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。